Evidence map›Paper›PMID 32065308›Full record

ReviewClinical and experimental medicine2020

Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature.

Giacomo Coltro, Francesco Mannelli, Federica Vergoni, Raffaella Santi, Daniela Massi, Luisa Margherita Siliani, Antonella Marzullo, Stefania Bonifacio, Elisabetta Pelo, Annalisa Pacilli and 6 more

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Clinical and experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Giacomo ColtroCRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy.
Francesco MannelliCRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy.
Federica VergoniIstologia Patologica e Diagnostica Molecolare, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Raffaella SantiIstologia Patologica e Diagnostica Molecolare, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Daniela MassiIstologia Patologica e Diagnostica Molecolare, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Luisa Margherita SilianiDivision of Oncological and Robotic Surgery, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Antonella MarzulloDivision of Genetic Diagnosis, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Stefania BonifacioDivision of Genetic Diagnosis, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Elisabetta PeloDivision of Genetic Diagnosis, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Annalisa PacilliCRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy.
Chiara PaoliCRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy.
Annalisa FranciCRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy.
Laura CalabresiCRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy.
Alberto BosiHematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Alessandro Maria VannucchiCRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy.
Paola GuglielmelliCRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy. paola.guglielmelli@unifi.it.ORCID http://orcid.org/0000-0003-1809-284X
Azienda Ospedaliero-Universitaria Careggi · IT

Funding

Associazione Italiana per la Ricerca sul Cancro 21267Istituto Toscano Tumori (IT) 2013Istituto Toscano Tumori (IT) CUP B16D14001130002Ministero della Salute GR-2011-02352109
6 · The paper itself

Abstract

Splenomegaly is a key clinical manifestation of myelofibrosis, and splenectomy is currently indicated in patients with drug refractory, symptomatic splenomegaly or with the aim of improving refractory cytopenias. Transformation to acute myeloid leukemia occurs in up to 20% of patients with myelofibrosis, while cases of myeloid sarcoma have been reported very unfrequently. In this manuscript, we report the case of a 60-year-old man with a history of primary myelofibrosis who underwent splenectomy because of drug-refractory massive splenomegaly, systemic symptoms and anemia. At the opening of the peritoneal cavity, the spleen resulted massively enlarged and tenaciously entrapped by a pervasive neoplastic-like tissue. The extensive involvement of the abdomen fatally complicated the surgical procedure. At postmortem examination, the spleen showed a diffuse infiltration of immature cells that were also found in the peritoneum, bowel, liver, lungs and myocardium. After immunohistochemical, cytogenetic, flow cytometric and molecular characterization of neoplastic population, a diagnosis of disseminated myeloid sarcoma of the spleen was made. This case report highlights a very unusual case of myeloid sarcoma originating from the spleen in a patient with myelofibrosis who had no evidence of bone marrow or peripheral blood involvement by leukemic cells. Molecular characterization showed that leukemic cells originated from the founding clone of the chronic phase. The sarcoma could not be suspected based on clinical findings and was diagnosed only at the time of surgical procedure and autopsy. This case suggests that leukemic transformation of myelofibrosis can originate outside the bone marrow and, presumably rarely, present as a granulocytic sarcoma.

Indexed as

HumansMaleMiddle AgedPrimary MyelofibrosisSarcoma, MyeloidSplenomegalyCalreticulinLeukemic transformationMyelofibrosisMyeloid sarcomaRuxolitinibSplenectomy

Identifiers

PMID32065308
OpenAlexW3006730740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.